Beximco Profit Tumble Continues Amid Hostile Macro Climate

Company Continues To Deliver Revenue Growth Alongside Profit Decline

10 May 2023

Beximco faced another quarter of declining profits despite growing revenue, as external headwinds including increased production costs took their toll on the firm.

A significant shareholder has opted to exit the business • Source: Shutterstock

Bangladeshi generics giant Beximco Pharmaceuticals Ltd. continued its quarterly trend of declining profits, despite net revenue growth, as macroeconomic factors dragged down its bottom line.

The firm has been warning shareholders of this anticipated decline for some time now, cautioning in November that headwinds such as the war in Ukraine, supply chain disruptions and record depreciation of local currency were likely to have an impact from Q1 2023 onward

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Viatris Awaits ‘Significant Rebound’ At Indore In 2026 After Painful Q1 Bite

14 May 2025

• By Dean Rudge

Viatris continues to make progress on remediation at the firm’s stricken manufacturing facility in Indore, India, following a warning letter and import alert delivered at the tail end of 2024.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

14 May 2025

• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

13 May 2025

• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Pfizer Discusses Tariffs Amid International Slump For Oncology Biosimilars Revenue

13 May 2025

• By Adam Zamecnik

Reflecting conversations across the wider pharmaceutical industry, Pfizer’s earnings call for the first quarter of 2025 focused on the sector’s response to the potential imposition of tariffs by the Trump administration.